- Home
- UCL vs OCUP Comparison
UCL vs OCUP Comparison
Compare UCL & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- OCUP
- Stock Information
- Founded
- UCL 2014
- OCUP 2018
- Country
- UCL Hong Kong
- OCUP United States
- Employees
- UCL N/A
- OCUP N/A
- Industry
- UCL Telecommunications Equipment
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- OCUP Health Care
- Exchange
- UCL Nasdaq
- OCUP Nasdaq
- Market Cap
- UCL 48.4M
- OCUP 53.1M
- IPO Year
- UCL 2020
- OCUP N/A
- Fundamental
- Price
- UCL $1.26
- OCUP $1.32
- Analyst Decision
- UCL
- OCUP Strong Buy
- Analyst Count
- UCL 0
- OCUP 3
- Target Price
- UCL N/A
- OCUP $18.67
- AVG Volume (30 Days)
- UCL 20.1K
- OCUP 85.0K
- Earning Date
- UCL 11-13-2024
- OCUP 11-11-2024
- Dividend Yield
- UCL N/A
- OCUP N/A
- EPS Growth
- UCL N/A
- OCUP N/A
- EPS
- UCL 0.12
- OCUP N/A
- Revenue
- UCL $86,076,000.00
- OCUP $16,449,000.00
- Revenue This Year
- UCL $11.23
- OCUP N/A
- Revenue Next Year
- UCL $27.52
- OCUP $258.69
- P/E Ratio
- UCL $10.82
- OCUP N/A
- Revenue Growth
- UCL 10.63
- OCUP N/A
- 52 Week Low
- UCL $1.17
- OCUP $1.15
- 52 Week High
- UCL $2.96
- OCUP $3.53
- Technical
- Relative Strength Index (RSI)
- UCL 42.81
- OCUP 47.79
- Support Level
- UCL $1.21
- OCUP $1.25
- Resistance Level
- UCL $1.43
- OCUP $1.35
- Average True Range (ATR)
- UCL 0.06
- OCUP 0.07
- MACD
- UCL 0.00
- OCUP 0.01
- Stochastic Oscillator
- UCL 23.91
- OCUP 25.00
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.